公开(公告)号：US11541034B2

公开(公告)日：2023-01-03

申请号：US17554091

申请日：2021-12-17

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: A61K31/401 ,  A61K31/403 ,  C07D403/12 ,  A61K31/427 ,  A61P31/14

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20220142976A1

公开(公告)日：2022-05-12

申请号：US17554091

申请日：2021-12-17

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: A61K31/403 ,  A61K31/427 ,  A61P31/14 ,  C07D403/12

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US11542270B2

公开(公告)日：2023-01-03

申请号：US16912828

申请日：2020-06-26

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Leanne Marie Buzon ,  Kevin James Filipski ,  David Andrew Griffith ,  Bethany Lyn Kormos ,  Luis Angel Martinez-Alsina ,  Russell Alan Miller ,  Matthew Richard Reese ,  Rachel Jane Roth Flach ,  Yuan Zhang

IPC: C07D495/04 ,  A61K31/155 ,  A61K31/4985 ,  A61K31/7048 ,  A61K45/06

Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

公开(公告)号：US11351149B2

公开(公告)日：2022-06-07

申请号：US17395139

申请日：2021-08-05

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: C07D403/12 ,  A61K31/403 ,  A61P31/14 ,  A61K31/427

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20210087204A1

公开(公告)日：2021-03-25

申请号：US17078257

申请日：2020-10-23

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Leanne Marie Buzon ,  Kevin James Filipski ,  David Andrew Griffith ,  Bethany Lyn Kormos ,  Luis Angel Martinez-Alsina ,  Russell Alan Miller ,  Matthew Richard Reese ,  Rachel Jane Roth Flach ,  Yuan Zhang

IPC: C07D495/04

Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

公开(公告)号：US20230339930A1

公开(公告)日：2023-10-26

申请号：US18004996

申请日：2021-07-07

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Qingyi Yang

IPC: C07D417/14 ,  A61P31/14

CPC classification number: C07D417/14 ,  A61P31/14

Abstract: The invention relates to compounds of Formula I




wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

公开(公告)号：US20220363673A1

公开(公告)日：2022-11-17

申请号：US17619912

申请日：2020-06-24

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Christopher Ryan Butler ,  Kevin James Filipski ,  Bethany Lyn Kormos ,  Luis Angel Martinez-Alsina ,  Russell Alan Miller ,  Kiyoyuki Omoto ,  Brian Raymer ,  Matthew Richard Reese ,  Rachel Jane Roth Flach ,  Yuan Zhang

IPC: C07D409/04 ,  A61K45/06 ,  A61K31/41 ,  A61P3/10 ,  A61P9/04

Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

公开(公告)号：US20220257563A1

公开(公告)日：2022-08-18

申请号：US17660270

申请日：2022-04-22

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Qingyi Yang

IPC: A61K31/403 ,  A61P31/14 ,  C07D403/12 ,  A61K31/427 ,  A61K31/401

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20230120254A1

公开(公告)日：2023-04-20

申请号：US17932151

申请日：2022-09-14

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Qingyi Yang

IPC: A61K31/403 ,  A61P31/14 ,  A61K31/427 ,  C07D403/12 ,  A61K31/401

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20220062232A1

公开(公告)日：2022-03-03

申请号：US17395139

申请日：2021-08-05

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: A61K31/403 ,  C07D403/12 ,  A61K31/427 ,  A61P31/14

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.